Savara (SVRA) Climbs 27.8% Ahead of 2 Health Conferences

We recently published 10 Small Caps With Big Double-Digit Gains. Savara Inc. (NASDAQ:SVRA) is one of the top performers of last week.

Savara soared by 27.84 percent week-on-week, as investors positioned their portfolios ahead of business updates from its participation in two conferences this week.

According to the company, members of its management team will host one-on-one meetings and participate in fireside chats at the Piper Sandler 37^th Annual Healthcare Conference on Tuesday, December 2, and at the Evercore ISI 8^th Annual Healthcare Conference on Thursday, December 4.

Investors will closely watch out for updates about the company’s business, alongside cues about its outlook.

Earlier this month, Savara Inc. (NASDAQ:SVRA) announced that it widened its net loss attributable to shareholders by 21.9 percent to $29.56 million from $24.2 million in the same period last year.

Total operating expenses also grew by 14.7 percent to $30.25 million from $26.3 million year-on-year, amid 1.4 percent higher research and development costs related to its Molbreevi program.

Molbreevi is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP).

While we acknowledge the potential of SVRA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.